



Supplement figure 6. Median Progression Free Survival (months) in MTC control patients (PFS)

PFS in this group was 11.2 months [95%CI 9.2 – 13.2; Q=60.3, X²(d.f. 1), p<0.001, I²=98.3%; z=11.05, p<0.001]